Life Science Company News

Reset
Results 281 - 300 out of 500 displayed.
«  1  2  3  4  5  6  7  8  9  10  11  12  13  14 15  16  17  18  19  20  21  22  23  24  25 »

Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020

Read more ››
By: PR Newswire Association LLC. - 05 Jun 2023

Edward W. Marple, A.B. (Harvard), MBA (Virginia), joins Paraza Pharma as Executive Vice-President, Development

Read more ››
By: PR Newswire Association LLC. - 05 Jun 2023

VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma

Read more ››
By: PR Newswire Association LLC. - 05 Jun 2023

Innovent Presents Phase 1b Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2023 ASCO Annual Meeting

Read more ››
By: PR Newswire Association LLC. - 05 Jun 2023
Related companies:  Innovent Biologics (USA), Inc.

Turn Biotechnologies Founder to be Featured Speaker at Japanese Society of Anti-Aging Medicine Meeting

Read more ››
By: PR Newswire Association LLC. - 05 Jun 2023
Related companies:  Turn Biotechnologies, Inc.

Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy

Read more ››
By: GlobeNewswire - 04 Jun 2023
Related companies:  G1 Therapeutics, Inc.

Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma

Read more ››
By: GlobeNewswire - 04 Jun 2023
Related companies:  Day One Biopharmaceuticals, Inc.

Phase 3 SWOG Cancer Research Network trial, led by a City of Hope researcher, demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy

Read more ››
By: PR Newswire Association LLC. - 04 Jun 2023
Related companies:  City of Hope Alpha Clinic for Cell Therapy

AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023

Read more ››
By: PR Newswire Association LLC. - 04 Jun 2023
Related companies:  Amgen Inc.

Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma

Read more ››
By: PR Newswire Association LLC. - 04 Jun 2023

New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33.6 Months of Follow-Up with First-Line Use of RYBREVANT® (amivantamab-vmjw) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR

Read more ››
By: PR Newswire Association LLC. - 04 Jun 2023

Roswell Park Study May Provide Clues to Treating Colorectal Cancer More Effectively in Younger Patients

A novel study led by medical oncologists Deepak Vadehra, DO, and Sarbajit Mukherjee, MD, MS, of Roswell Park Comprehensive Cancer Center is shedding light on factors that may affect treatment response in younger people with colorectal cancer. That information could guide the development of new treatments... Read more ››
By: PR Newswire Association LLC. - 04 Jun 2023
Related companies:  Roswell Park Comprehensive Cancer Center

Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting

Read more ››
By: PR Newswire Association LLC. - 04 Jun 2023
Related companies:  Innovent Biologics (USA), Inc.

Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Read more ››
By: GlobeNewswire - 03 Jun 2023
Related companies:  Replimune Group Inc.

Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)

Read more ››
By: GlobeNewswire - 03 Jun 2023
Related companies:  Cogent Biosciences, Inc.

Janssen Presents First Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma

Read more ››
By: GlobeNewswire - 03 Jun 2023
Related companies:  Janssen Pharmaceutica NV

Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

Read more ››
By: GlobeNewswire - 03 Jun 2023
Related companies:  Sutro Biopharma, Inc.

Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial

Read more ››
By: GlobeNewswire - 03 Jun 2023
Related companies:  Evaxion Biotech A/S

Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting

Read more ››
By: PR Newswire Association LLC. - 03 Jun 2023

Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma

Read more ››
By: PR Newswire Association LLC. - 03 Jun 2023
Results 281 - 300 out of 500 displayed.
«  1  2  3  4  5  6  7  8  9  10  11  12  13  14 15  16  17  18  19  20  21  22  23  24  25 »

Enhance your business development with Biotechgate
Try for free »